[go: up one dir, main page]

GB202309695D0 - Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups - Google Patents

Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups

Info

Publication number
GB202309695D0
GB202309695D0 GBGB2309695.1A GB202309695A GB202309695D0 GB 202309695 D0 GB202309695 D0 GB 202309695D0 GB 202309695 A GB202309695 A GB 202309695A GB 202309695 D0 GB202309695 D0 GB 202309695D0
Authority
GB
United Kingdom
Prior art keywords
patient subgroups
cancer patient
specific cancer
novel
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2309695.1A
Other versions
GB2631308A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research
Cancer Research Technology Ltd
Original Assignee
Institute of Cancer Research
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research, Cancer Research Technology Ltd filed Critical Institute of Cancer Research
Priority to GB2309695.1A priority Critical patent/GB2631308A/en
Publication of GB202309695D0 publication Critical patent/GB202309695D0/en
Priority to PCT/GB2024/051658 priority patent/WO2025003680A1/en
Publication of GB2631308A publication Critical patent/GB2631308A/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GB2309695.1A 2023-06-27 2023-06-27 Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups Pending GB2631308A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB2309695.1A GB2631308A (en) 2023-06-27 2023-06-27 Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups
PCT/GB2024/051658 WO2025003680A1 (en) 2023-06-27 2024-06-27 Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2309695.1A GB2631308A (en) 2023-06-27 2023-06-27 Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups

Publications (2)

Publication Number Publication Date
GB202309695D0 true GB202309695D0 (en) 2023-08-09
GB2631308A GB2631308A (en) 2025-01-01

Family

ID=87517611

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2309695.1A Pending GB2631308A (en) 2023-06-27 2023-06-27 Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups

Country Status (2)

Country Link
GB (1) GB2631308A (en)
WO (1) WO2025003680A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8729048B2 (en) 2011-11-22 2014-05-20 Mayo Foundation For Medical Education And Research Methods and materials for assessing responsiveness to PARP inhibitors and platinating agents
WO2014205105A1 (en) 2013-06-19 2014-12-24 The Regents Of The University Of California Biomarkers of response to inhibition of poly-adp ribose polymerase (parp) in cancer
WO2021050937A1 (en) * 2019-09-12 2021-03-18 The Wistar Institute Of Anatomy And Biology Methods for the treatment of arid1a-deficient cancers
WO2022051491A1 (en) * 2020-09-02 2022-03-10 Senhwa Biosciences, Inc. Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
WO2022125470A1 (en) * 2020-12-07 2022-06-16 Foundation Medicine, Inc. Comprehensive genomic profiling (cgp) of metastatic invasive lobular carcinomas reveals heterogeneity
US20240269144A1 (en) * 2021-06-02 2024-08-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and kits for the detection of malignancies

Also Published As

Publication number Publication date
WO2025003680A1 (en) 2025-01-02
GB2631308A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
IL287643A (en) Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
IL299167A (en) Compositions and methods for treatment of gene therapy patients
PL3797741T3 (en) Portable thermal therapy and support apparatus for emergency medical treatment
IL289787A (en) Antibody combinations for treatment of cancer in specific patients
IL307964A (en) Combination therapy for cancer treatment
IL299339A (en) Antibodies and methods for treating claudin-associated diseases
GB202018015D0 (en) Composition and methods for the treatment of intestinal cancer
GB202006072D0 (en) Method of selecting patients for treatment with cmbination therapy
GB202309695D0 (en) Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups
GB2594489B (en) Patient positioning for radiotherapy treatment
GB202016173D0 (en) Demethylation apparatus and cancer therapy apparatus comprising same, and demethylation method and aparatus for cancer therapy using same
GB202102026D0 (en) Medical apparatus and method
EP4082577A4 (en) Cancer treatment method and medicine
EP4284519A4 (en) Methods for treating and ameliorating cancer
EP4130024A4 (en) Method for predicting efficacy of treatment of lung cancer patient using immune checkpoint inhibitor
EP4134098A4 (en) Method of cancer therapy
EP4190911A4 (en) Method and drug for tumor treatment
IL317115A (en) Methods for identifying and treating diseases
GB202010820D0 (en) Patient repositioning apparatus and method
GB202102530D0 (en) Method of selecting patients for treatment with combination therapy
GB202302196D0 (en) Medical apparatus and method
GB202202014D0 (en) Medical apparatus and method
CA235353S (en) Medical treatment apparatus
PT4117667T (en) Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy
IL311229A (en) Triple-agent therapy for cancer treatment